Meeting
2024 ASCO Annual Meeting
Circulating tumor DNA analysis in patients with BRAF-mutated metastatic cutaneous melanoma treated with BRAF and MEK inhibitors: Analysis of the OPTIMEL study.
Authors
Alexandre Harle
Institut de Cancérologie de Lorraine, Service de Biopathologie, CNRS UMR 7039 CRAN Université de Lorraine, Nancy, France
Alexandre Harle , Albane Marie Lhuillier , Nassim Sahki , Florence Granel Brocard , Amélie Schoeffler , Hélène Martin , Philippe Muller , Alice Hervieu , Marie Rouyer , Marie Husson , Denise Bechet , Magali Lefebvre , Julien Scala Bertola , Nicolas Gambier , Allan Kolodziej , Jean-Louis Merlin , Lionnel Geoffrois
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT03416933
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 9541)
DOI
10.1200/JCO.2024.42.16_suppl.9541
Abstract #
9541
Poster Bd #
325
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Association of ultra-sensitive ctDNA assay to identify actionable variants and response to immune checkpoint inhibitor (ICI) therapy in metastatic melanoma.
First Author: Christoffer Gebhardt
Poster
2022 ASCO Annual Meeting
Myeloma developing regimens using genomics (MyDRUG) trial: Results from the RAS mutation targeting arm.
First Author: Shaji Kumar
Poster
2020 ASCO Virtual Scientific Program
Circulating tumor DNA (ctDNA) using Guardant360 to predict response in BRAF V600 WT metastatic melanoma (MM) patients (pts) receiving immune checkpoint inhibitors (ICI).
First Author: Jenny HJ Lee
Poster
2019 ASCO Annual Meeting
Baseline cfDNA characteristics and evolution of cfDNA profile during treatment with selective FGFR inhibitor TAS-120.
First Author: Tyler J. Moss